No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
CT Enterprise (03839.HK) reported a profit of 5.605 million US dollars in the first three quarters.
The ct enterprise issued an announcement on November 12, stating that for the nine months ending on September 30, 2024, the company's revenue was 0.17 billion US dollars, compared to 0.12 billion US dollars in the same period last year; the net profit for the period was 5.605 million US dollars, compared to 2.177 million US dollars in the same period last year.
Express News | Chia Tai Enterprises International Ltd - Nine Months Profit US$5.6 Mln
CT ENTERPRISE: Unaudited Results for the Nine Months Ended 30 September 2024
Not Many Are Piling Into Chia Tai Enterprises International Limited (HKG:3839) Stock Yet As It Plummets 26%
